Phase II study of everolimus for recurrent or progressive pediatric ependymoma

Review Oncology

Recent advances and limitations of mTOR inhibitors in the treatment of cancer

Eunus S. Ali et al.

Summary: The PI3K-Akt-mTOR signaling pathway plays a crucial role in various biological activities. Targeting mTOR with rapamycin-derived compounds has proven effective in suppressing mTOR activity and reducing cancer cell growth.

CANCER CELL INTERNATIONAL (2022)

添加到收藏夹

Article Cell Biology

Nucleoporin TPR (translocated promoter region, nuclear basket protein) upregulation alters MTOR-HSF1 trails and suppresses autophagy induction in ependymoma

Firli Rahmah Primula Dewi et al.

Summary: Children with ependymoma face high mortality rates due to resistance to conventional therapy. Targeting the oncogenic role of TPR in regulating HSF1 and MTOR signaling pathways may serve as a potential therapeutic approach for ependymoma treatment. TPR expression levels could potentially act as a biomarker for ependymoma, with pharmacological interventions showing promise in reducing tumor size in vivo.

AUTOPHAGY (2021)

添加到收藏夹

Article Oncology

Local and systemic therapy of recurrent ependymoma in children and adolescents: short- and long-term results of the E-HIT-REZ 2005 study

Jonas E. Adolph et al.

Summary: In recurrent ependymomas in children and adolescents, the extent of resection is the most important predictor of survival. Focal re-irradiation is a useful approach for patients who cannot achieve complete resection, but does not provide additional benefit for those with complete or near-total resection. In some cases, disease stabilization for longer periods was achieved with TMZ.

NEURO-ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Systemic chemotherapy of pediatric recurrent ependymomas: results from the German HIT-REZ studies

Jonas E. Adolph et al.

Summary: The study found no general survival advantage for the use of chemotherapy in recurrent EPN, but showed that chemotherapy can extend survival in individual cases with incomplete resection. Sirolimus demonstrated the best response rate, duration of response, and time to progression among all drugs analyzed, suggesting it may warrant further investigation.

JOURNAL OF NEURO-ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Outcomes after first relapse of childhood intracranial ependymoma

Jessica W. Tsai et al.

Summary: Ependymoma is the third most common malignant CNS tumor in children, with a poor prognosis upon relapse. Complete resection is associated with localized disease, and radiation therapy may delay progression. Some patients present with metastatic disease at first relapse.

PEDIATRIC BLOOD & CANCER (2021)

添加到收藏夹

Article Cell Biology

Targeting integrated epigenetic and metabolic pathways in lethal childhood PFA ependymomas

Pooja Panwalkar et al.

Summary: Childhood posterior fossa group A ependymomas (PFAs) have limited treatment options and poor prognoses compared to group B ependymomas (PFBs). PFAs exhibit enhanced glycolysis and tricarboxylic acid (TCA) cycle metabolism, with high expression of glycolytic genes associated with a poor outcome. These tumors also show high EZHIP expression linked to a dismal prognosis and elevated activating mark histone H3 lysine 27 acetylation (H3K27ac). Repurposing the antidiabetic drug metformin has shown therapeutic efficacy in vitro and in vivo in patient-derived PFA xenografts by targeting integrated metabolic/epigenetic pathways.

SCIENCE TRANSLATIONAL MEDICINE (2021)

添加到收藏夹

Article Medicine, Research & Experimental

Identification of key methylation differentially expressed genes in posterior fossa ependymoma based on epigenomic and transcriptome analysis

Guanyi Wang et al.

Summary: Through methods like WGCNA analysis, key hub genes for EPN-PF were identified, indicating their involvement in multiple important cellular signaling pathways that may impact patient prognosis.

JOURNAL OF TRANSLATIONAL MEDICINE (2021)

添加到收藏夹

Article Oncology

Second series by the Italian Association of Pediatric Hematology and Oncology of children and adolescents with intracranial ependymoma: an integrated molecular and clinical characterization with a long-term follow-up

Maura Massimino et al.

Summary: A 10-year follow-up study of 160 ependymoma patients revealed the association between specific molecular features and patient outcomes. Late relapses occurred in 6.2% of patients, with PFB patients showing a better prognosis. Specific molecular features such as 1q gain and CDKN2A loss were associated with dissemination.

NEURO-ONCOLOGY (2021)

添加到收藏夹

Article Oncology

A phase I study of sirolimus in combination with metronomic therapy (CHOAnome) in children with recurrent or refractory solid and brain tumors

Muna Qayed et al.

PEDIATRIC BLOOD & CANCER (2020)

添加到收藏夹

Article Oncology

A retrospective analysis of recurrent pediatric ependymoma reveals extremely poor survival and ineffectiveness of current treatments across central nervous system locations and molecular subgroups

Timothy A. Ritzmann et al.

PEDIATRIC BLOOD & CANCER (2020)

添加到收藏夹

Article Clinical Neurology

EPEN-54. ACNS0831, PHASE III RANDOMIZED TRIAL OF POST-RADIATION CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED EPENDYMOMA AGES 1 TO 21 YEARS

Amy Smith et al.

NEURO-ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Conformal Radiation Therapy for Pediatric Ependymoma, Chemotherapy for Incompletely Resected Ependymoma, and Observation for Completely Resected, Supratentorial Ependymoma

Thomas E. Merchant et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Review Oncology

A systematic review and meta-analysis of outcomes in pediatric, recurrent ependymoma

Lennox Byer et al.

JOURNAL OF NEURO-ONCOLOGY (2019)

添加到收藏夹

Article Neurosciences

Improved risk-stratification for posterior fossa ependymoma of childhood considering clinical, histological and genetic features - a retrospective analysis of the HIT ependymoma trial cohort

Stephanie T. Juenger et al.

ACTA NEUROPATHOLOGICA COMMUNICATIONS (2019)

添加到收藏夹

Article Oncology

Craniospinal irradiation as part of re-irradiation for children with recurrent intracranial ependymoma

Derek S. Tsang et al.

NEURO-ONCOLOGY (2019)

添加到收藏夹

Article Oncology

A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors

Oren J. Becher et al.

PEDIATRIC BLOOD & CANCER (2017)

添加到收藏夹

Article Clinical Neurology

Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome

Pooja Panwalkar et al.

ACTA NEUROPATHOLOGICA (2017)

添加到收藏夹

Article Oncology

Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis

Vijay Ramaswamy et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

添加到收藏夹

Article Cell Biology

Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas

Jill Bayliss et al.

SCIENCE TRANSLATIONAL MEDICINE (2016)

添加到收藏夹

Article Multidisciplinary Sciences

Re-irradiation of recurrent pediatric ependymoma: modalities and outcomes: a twenty-year survey

Maria Jesus Lobon et al.

SPRINGERPLUS (2016)

添加到收藏夹

Article Oncology

Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups

Kristian W. Pajtler et al.

CANCER CELL (2015)

添加到收藏夹

Article Multidisciplinary Sciences

Epigenomic alterations define lethal CIMP-positive ependymomas of infancy

S. C. Mack et al.

NATURE (2014)

添加到收藏夹

Article Oncology

PI3K Pathway Activation Provides a Novel Therapeutic Target for Pediatric Ependymoma and Is an Independent Marker of Progression-Free Survival

Hazel A. Rogers et al.

CLINICAL CANCER RESEARCH (2013)

添加到收藏夹

Article Medicine, General & Internal

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial

David Neal Franz et al.

LANCET (2013)

添加到收藏夹

Review Oncology

mTOR inhibitors in cancer therapy

Yekaterina Y. Zaytseva et al.

CANCER LETTERS (2012)

添加到收藏夹

Article Oncology

Survival Benefit for Pediatric Patients With Recurrent Ependymoma Treated With Reirradiation

Eric Bouffet et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)

添加到收藏夹

Editorial Material Oncology

Phosphatidylinositide-3-Kinase Inhibitors: Addressing Questions of Isoform Selectivity and Pharmacodynamic/Predictive Biomarkers in Early Clinical Trials

Paul A. Clarke et al.

JOURNAL OF CLINICAL ONCOLOGY (2012)

添加到收藏夹

Article Oncology

Delineation of Two Clinically and Molecularly Distinct Subgroups of Posterior Fossa Ependymoma

Hendrik Witt et al.

CANCER CELL (2011)

添加到收藏夹

Article Oncology

mTORC1 activation in childhood ependymoma and response to sirolimus

Daniel C. Bowers et al.

JOURNAL OF NEURO-ONCOLOGY (2011)

添加到收藏夹

Review Oncology

Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals

Terence O'Reilly et al.

TRANSLATIONAL ONCOLOGY (2010)

添加到收藏夹

Article Clinical Neurology

Management strategies for recurrent ependymoma in the paediatric population

M. Sangra et al.

CHILDS NERVOUS SYSTEM (2009)

添加到收藏夹

Article Clinical Neurology

Salvage chemotherapy for metastatic and recurrent ependymoma of childhood

Eric Bouffet et al.

CHILDS NERVOUS SYSTEM (2009)

添加到收藏夹

Article Oncology

Relapsed intracranial ependymoma in children in the UK: Patterns of relapse, survival and therapeutic outcome

B. Messahel et al.

EUROPEAN JOURNAL OF CANCER (2009)

添加到收藏夹

Article Computer Science, Interdisciplinary Applications

Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support

Paul A. Harris et al.

JOURNAL OF BIOMEDICAL INFORMATICS (2009)

添加到收藏夹

Article Oncology

A retrospective study of surgery and reirradiation for recurrent ependymoma

Thomas E. Merchant et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2008)

添加到收藏夹

Article Oncology

Phase I study of everolimus in pediatric patients with refractory solid tumors

Maryam Fouladi et al.

JOURNAL OF CLINICAL ONCOLOGY (2007)

添加到收藏夹

Article Clinical Neurology

Rapamycin causes regression of astrocytomas in tuberous sclerosis complex

DN Franz et al.

ANNALS OF NEUROLOGY (2006)

添加到收藏夹

Article Oncology

A feasibility trial of antiangiogenic (Metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer

MW Kieran et al.

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2005)

添加到收藏夹

Phase II study of everolimus for recurrent or progressive pediatric ependymoma

相关参考文献

导出引文

分享论文